LINDEROTH, Emma,VILLER, Natasja Nielsen,UGER, Robert Adam,SLAVOVA-PETROVA, Penka Slavcheva
申请号：
EP17868118
公开号：
EP3534964A4
申请日:
2017.11.01
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
CD47− disease cells such as cancer cells are treated using a combination of CD47 blockade drug and a proteasome inhibitor. The anti-cancer effect of one drug enhances the 5 anti-cancer effect of the other. Specific combinations include SIRPαFc as CD47 blockade drug, and one of bortezomib, ixazomib and carfilzomib as proteasome inhibitor. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.
